Alpha Cognition Inc ACOGF

Primary Symbol: C.ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

CSE:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by culturedpiggy01on Dec 09, 2021 4:18pm

97 Views

Post# 34216137

$ACOG.V 's new TBI clinical study featured in The Power Play

$ACOG.v has been featured in the The Power Play by The Market Herald as they

announce results from pre-clinical study of ALPHA-1062. They reported that administering ALPHA-1062 reduced the extent of the functional deficit and improved functional recovery of Traumatic Brain Injury animals compared to untreated animals. more on the ongoing clinical study here: https://themarketherald.ca/alpha-cognition-tsxvacog-announces-results-from-pre-clinical-study-of-alpha-1062-2021-12-06/

td, $ACOG.v trading at $1.21 with market cap at $74.41 M

<< Previous

Bullboard Posts

Next >>

Northstar Gold surveys large potential copper resource extension